MAIA Biotechnology, Inc.
MAIANYSE
$1.30
↓ -2.3%Jul 17 close · end-of-day
Price
1Y↓ -24.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$58.8M
Enterprise Value
$58.8M
P/E
—
P/S
—
P/B
2.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$24.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-87.3%
ROIC
-73.4%
Debt / Equity
—
Net Cash
$0.00
Return 1Y
-27.0%
Company profile
We are a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. We were incorporated in Delaware in August 2018, and we have operations in Chicago, Illinois, with some of our team members setup virtually and working remotely in California, Nevada and Florida. Our principal executive office is located at 444 West Lake Street, Suite 1700, Chicago, IL.
- CEO
- Vlad Vitoc
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 9
- Headquarters
- Illinois
- Website
- MAIABiotech.com
Management & directors
- Gryaznov SergeiChief Scientific Officer
- Vitoc VladChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
MAIA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.14↓ -12.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$7.8M | -$16.2M | -$20.2M | -$17.0M | -$24.3M |
| Net income | — | — | — | -$23.3M | -$22.4M |
| Diluted EPS | -$2.37 | -$1.75 | -$1.49 | -$1.05 | -$0.70 |
| Operating cash flow | -$4.1M | -$12.1M | -$13.1M | -$15.7M | -$18.8M |
| Free cash flow | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.8M | -$4.2M | -$5.0M | -$5.4M | -$5.2M | -$9.4M | -$4.3M | -$6.9M |
| Net income | -$8.9M | -$2.7M | -$3.6M | -$4.5M | -$5.3M | -$8.9M | -$3.6M | -$6.4M |
| Diluted EPS | -$0.40 | -$0.11 | -$0.08 | -$0.16 | -$0.18 | -$0.27 | -$0.09 | -$0.14 |
| Operating cash flow | -$4.7M | -$3.5M | -$3.9M | -$4.2M | -$4.1M | -$3.5M | -$7.0M | -$5.3M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-01 | Vitoc Vlad· Chief Executive Officer | Buy | 72,700 | $1.39 | $100,885.79 | filing |
| 2026-06-01 | Smith Stan | Buy | 75,000 | $1.34 | $100,200.00 | filing |
| 2026-06-01 | Gryaznov Sergei· Chief Scientific Officer | Buy | 2,000 | $1.35 | $2,690.00 | filing |
| 2025-12-22 | Louie Ngar Yee | Buy | 81,699 | $1.22 | $99,999.58 | filing |
| 2025-12-22 | Smith Stan | Buy | 57,189 | $1.22 | $69,999.34 | filing |
| 2025-12-22 | CHAOUKI STEVEN M | Buy | 40,849 | $1.22 | $49,999.18 | filing |
| 2025-12-05 | Smith Stan | Buy | 4,580 | $1.20 | $5,496.00 | filing |
| 2025-12-05 | Smith Stan | Buy | 4,580 | $1.20 | $5,494.63 | filing |
| 2025-12-05 | Smith Stan | Buy | 4,580 | $1.19 | $5,450.20 | filing |
| 2025-11-28 | Vitoc Vlad· Chief Executive Officer | Buy | 50,000 | $1.14 | $56,830.00 | filing |
| 2025-11-26 | Vitoc Vlad· Chief Executive Officer | Buy | 22,000 | $1.05 | $23,018.60 | filing |
| 2025-11-25 | Vitoc Vlad· Chief Executive Officer | Buy | 10,500 | $0.97 | $10,144.05 | filing |
| 2025-11-25 | Vitoc Vlad· Chief Executive Officer | Buy | 10,500 | $0.97 | $10,144.05 | filing |
| 2025-11-25 | Luput Cristian | Buy | 10,000 | $0.98 | $9,785.00 | filing |
| 2025-11-24 | Vitoc Vlad· Chief Executive Officer | Buy | 10,000 | $0.99 | $9,891.00 | filing |
| 2025-11-21 | Vitoc Vlad· Chief Executive Officer | Buy | 1,800 | $0.92 | $1,656.00 | filing |
| 2025-10-01 | Smith Stan | Buy | 19,230 | $1.30 | $24,999.00 | filing |
Latest 17 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.